McKesson (MCK) Earnings Expected to Grow: Should You Buy?

McKesson (MCK) is anticipated to report robust Q2 2025 results on August 6, with consensus estimates projecting EPS of $8.23 (+4.4% YoY) on revenues of $96.08 billion (+21.2% YoY). Analysts have recently revised EPS estimates upward, and the company's positive Zacks Earnings ESP of +0.14% combined with a Zacks Rank #2 indicates a high probability of an earnings beat. This outlook positions MCK as a compelling earnings-beat candidate, though broader market dynamics and company fundamentals remain crucial considerations for investors.

Analysis

McKesson (MCK) is positioned for a potential earnings beat in its upcoming report for the quarter ended June 2025, driven by strong top-line growth expectations. Wall Street consensus projects a significant 21.2% year-over-year revenue increase to $96.08 billion, with forecasted earnings per share of $8.23, a 4.4% rise. Bullish sentiment is further evidenced by a 1.1% upward revision in the consensus EPS estimate over the past 30 days. Quantitative indicators support this outlook: the company holds a Zacks Rank #2 (Buy) and a positive Earnings ESP of +0.14%, a combination that historically predicts an earnings surprise approximately 70% of the time. This positive setup is reinforced by MCK's recent history of beating EPS estimates in three of the last four quarters. In contrast, industry peer Henry Schein (HSIC) faces a weaker outlook with an expected 4.1% YoY earnings decline and downward estimate revisions, highlighting McKesson's relative fundamental strength within the sector, even though both are likely to beat estimates.

Key Decisions for Investors

• Given the combination of a Zacks Rank #2 (Buy), a positive Earnings ESP, and recent upward estimate revisions, investors may consider the stock a compelling candidate for a positive earnings surprise on August 6.
• Traders should monitor not only the headline EPS figure but also the substantial 21.2% consensus revenue growth, as any deviation from this high expectation could significantly impact the market's reaction.
• Beyond the earnings print, the sustainability of any price move will depend heavily on management's forward-looking guidance; a strong earnings beat without an equally strong outlook may temper investor enthusiasm.
• The starkly different growth trajectories between McKesson (+21.2% revenue growth) and its peer Henry Schein (-4.1% EPS decline) could inform pair-trade strategies within the medical supplies sector.